MarkRLitzowMD

Oncology • Rochester, MN

Hematologic Oncology

Professor of Medicine, Mayo Medical School

Join to view full profile

Dr. Litzow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Litzow's full profile

Already have an account?

Office
200 1st St Sw
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1986 - 1989
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1980 - 1984
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1980

Certifications & Licensure

MN State Medical License 1981 - 2026
MT State Medical License 2013 - 2025
AZ State Medical License 2013 - 2024
FL State Medical License 2013 - 2024
IA State Medical License 2013 - 2024
MI State Medical License 2013 - 2024
ND State Medical License 2014 - 2024
WI State Medical License 2014 - 2023
CO State Medical License 2013 - 2021
GA State Medical License 2013 - 2021
NH State Medical License 2013 - 2021
ID State Medical License 2013 - 2020
IL State Medical License 2013 - 2020
KY State Medical License 2013 - 2020
MO State Medical License 2013 - 2020
KS State Medical License 2013 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Start of enrollment: 1993 May 07
Completed
Phase 3
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia Start of enrollment: 2000 Oct 04
Completed
Phase 2
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2000 Jun 01
Completed
Phase 2
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Withdrawn
Phase 2
The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection. Start of enrollment: 2001 Nov 01
Completed
Phase 3
Belinostat in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2006 May 01
Completed
Phase 2
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2008 Oct 01
Completed
Phase 2
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer Start of enrollment: 1998 Aug 01
Completed
Phase 1
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD) Start of enrollment: 2012 Mar 01
Withdrawn
Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes Start of enrollment: 2013 Mar 01
Completed
Phase 2
Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission Start of enrollment: 2012 Jul 01
Terminated
Phase 1, Phase 2
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Completed
Phase 2
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease Start of enrollment: 2016 Aug 01
Completed
Phase 2
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia Start of enrollment: 2022 Jun 01
Recruiting
Not Applicable
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
American Journal of Hematology. 2024-12-13
Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.
Joseph P McGuirk, Leland Metheny 3rd, Luis Pineiro, Mark Litzow, Scott D Rowley
Bone Marrow Transplantation. 2024-12-03
The use of haploidentical stem cell transplant as an alternative donor source in patients with decreased access to matched unrelated donors.
Christopher Graham, Mark Litzow
Hematology. 2024-12-01

Journal Articles

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...
Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
Does Matching for SNPs in the MHC Gamma Block in 10/10 HLA-Matched Unrelated Donor-Recipient Pairs Undergoing Allogeneic Stem Cell Transplant Improve Outcomes?
Eapen K Jacob, Shahrukh K Hashmi, Justin D Kreuter, William J Hogan, Dennis A Gastineau, Ann M Moyer, Mark Litzow, ScienceDirect

Abstracts/Posters

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopo...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Ly...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic S...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neo...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytos...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
Mark Litzow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Panoply of Immunotherapies for Adult B-Lineage Acute Lymphocytic Leukemia
60th American Society of Hematology Annual Meeting - 12/3/2018
A Panoply of Immunotherapies for Adult B-Lineage Acute Lymphocytic Leukemia
60th American Society of Hematology Annual Meeting - 12/1/2018
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Functional and Genomic Characterization of the Interaction between Acute Lymphoblastic Leukemia Cells and the Microenvironment Identifies Pathways for Therapeutic Inte...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with N...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Rando...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Promising Future of Acute Lymphoblastic Leukemia Treatment
2013 Annual Meeting, Chicago, Illinois, USA
The Promising Future of Acute Lymphoblastic Leukemia Treatment
American Society of Clinical Oncology, 2013 Annual Meeting, Chicago, Illinois, USA
Join now to see all

Authored Content

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018

Press Mentions

Chemotherapy and Tyrosine Kinase Inhibitor Therapy May Improve Overall Survival in ALLNovember 26th, 2024
myeloMATCH Program Opens Enrollment for Acute Myeloid Leukemia and MDSOctober 22nd, 2024
Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in MRD-Negative Remission from BCP-ALLAugust 12th, 2024
Join now to see all

Grant Support

Dendritic Cell Therapy Of Chronic Myelogenous LeukemiaNational Cancer Institute2001–2003
Trial Of Recombinant Interleukin-3 And GM-CSFNational Center For Research Resources1994–1996